Healthcare Products
4530787
C O N T R O L L E D O X I D A T I O N O F M I C R O B I A L L Y P R O D U C E D
C Y S T E I N E - C O N T A I N I N G P R O T E I N S
Ze'e Shaked, Sidney Wolfe assigned to Cetus Corporation
Method of oxidizing reduced cysteine- containing microbially produced synthetic pro- teins, such as synthetic IFN- beta or synthetic IL-2, in a controlled manner so that the synthetic proteins have the same disulfide bridging as their native counterparts. The oxidation employs o- iodosobenzoate as oxidizing agent and is carried out in an aqueous medium at a pH at least about one-half pH unit less than the pKa of the cysteines to be oxidized, a synthetic protein con- centration ofless than about 5 mg/ml, and an ox- idizing agent:protein mol ratio that is at least stoichiometric, provided that the oxidizing agent is in excess in the terminal portion of the reac- tion.
4530831
I N F E C T I O U S B U R S A L D I S E A S E V A C C I N E
Heinrich D Luttickem Daniel R W Cornelissen, Boxmeer, Netherlands assigned to Akzo N V
An Infectious Bursal Disease vaccine com- prising the virus strain deposited at the ATCC under No. VR-2041, a process for the prepara- tion thereof, and a method of controlling Infec- tious Bursal Disease of poultry by administering said vaccine.
4530832
M E T H O D O F V A C C I N A T I O N F O R P R E V E N T I O N O F B O R D E T E L L A B R O N C H I S E P T I C A I N F E C T I O N
Robert Goodnow. Floyd J Shade. Thomas Sloboth assigned to Schering Corporation
Viable cells of an avirulent self-clearing strain of B. bronchiseptica are administered as an intra- respiratory vaccine. An aqueous suspension of the cells is applied to the respiratory mucosa im- mediately after incorporating a non-inhibitory
PATENT ABSTRACTS 169
amount of a wetting agent promoting the mucosal implantation of the cells. Effective im- munization can thereby be obtained against dis- eases such as kennel cough in dogs and atrophic rhinitis in swine even through the strain of B. bronchiseptica is so highly attenuated that it is seff-clearing from the respiratory mucosa.
4530901
R E C O M B I N A N T D N A M O L E C U L E S A N D T H E I R U S E IN
P R O D U C I N G H U M A N I N T E R F E R O N - L I K E
P O L Y P E P T I D E S
Charles Weissmann, Zurich, Switzerland as- signed to Biogen N V
Recombinant DNA molecules and hosts trans- formed with them which produce polypeptides displaying a biological or immunological ac- tivity of human interferon, the gene coding for these polypeptides and methods of making and using these molecules, hosts, genes and poly- peptides. The recombinant DNA molecules are characterized by structural genes that code for a polypeptide displaying a biological or im- mulogical activity of human interferon. In ap- propriate hosts tbes¢ molecules permit the production and identification of genes and poly- peptides displaying a biological or immuno- logical activity of human interferon and their use in antiviral and antitumor or anticaneer agents.
4530908
D I A G N O S I S A N D T R E A T M E N T O F F L U K E I N F E C T I O N S W I T H M O N O C L O N A L A N T I B O D I E S
Mette Strand assigned to The Johns Hopkins University
Antibodies and antigens are disclosed which provide a method of detecting and a method of combating flukes. A diagnostic method for the determination of an active fluke infection in a warm-blooded animal is provided which com- prises the testing of body serum or body fluids for the presence of fluke spine glycoprotein or anti-spine antibodies. Fused cell hybrids ATCC HB-8086, ATCC HB-8087 and ATCC HB-8088, as well as the antibodies produced by the fused cell hybrids, are also provided.
